Follow us on

Drug makers gain; not too hurt by pricing cap

Source : REUTERS
Last Updated: Fri, Sep 28, 2012 08:56 hrs

Shares in pharmaceutical companies gain despite a recommendation by a ministry panel to cap drug prices given the proposal is seen as less hurtful than expected.

A panel of ministers recommended capping prices for 348 drugs deemed essential by calculating the weighted average of the market prices of all the brands with more than 1 percent market share.

The proposal, which will be forwarded to the cabinet within a week, is seen less disruptive than a cap based on cost-based pricing given the latter would have a more direct impact on profit margins.

Cipla gains 1.9 percent, Glenmark Pharmaceuticals is up 0.8 percent, GlaxoSmithKline Pharmaceutical is up 0.8 percent, while Lupin gains 0.2 percent.

blog comments powered by Disqus
most popular on facebook
talking point on sify finance